OTLK OUTLOOK THERAPEUTICS INC
Company Analysis
Latest News
🟢 Outlook Therapeutics is trading 5.33% up today after $485-per-vial LYTENAVA pricing announcement
Outlook Therapeutics is trading at $0.69, up 5.33%, as attention extends around the September 18 announcement of a $485-per-vial U.S. wholesale price for...
Outlook Therapeutics Sets U.S. Wholesale Price for LYTENAVA™ at $485 Per Vial
Outlook Therapeutics, Inc. has established the wholesale acquisition cost (WAC) for its product, LYTENAVA™, in the United States. This pricing announcement is...
🟢 Outlook Therapeutics is trading 5.8% up in pre-market as S&P 500, Nasdaq and Dow Jones rise
Outlook Therapeutics is trading at $0.72, up +5.82%, with the move appearing aligned with broader pre-market risk appetite. - No new company-specific...
🟢 Outlook Therapeutics is trading 5.5% up today with no newly reported company-specific catalyst identified
Outlook Therapeutics is trading 5.5% up at $0.71, with no newly reported company-specific catalyst identified for September 16, 2026. - Latest releases were...
🟢 Outlook Therapeutics is trading 5% up today
Outlook Therapeutics is trading 5.02% up now at $0.67, with no clear company-specific, sector, or macro catalyst established. - No new company-specific...
🟢 Outlook Therapeutics is trading 6.89% up today with no clear company-specific catalyst
Outlook Therapeutics is trading 6.89% up at $0.69, with the move appearing most consistent with speculative biotech-sector activity or stock-specific trading;...
🟢 Outlook Therapeutics is trading 5% up today with biotech-sector strength
Outlook Therapeutics is trading 5.22% up now at $0.66 after no specific catalyst was provided. - The available alert does not identify a company announcement,...
Outlook Therapeutics Appoints Kevin Lundquist as New CFO, Succeeding Lawrence Kenyon
Outlook Therapeutics announced a transition in its executive leadership, appointing Kevin Lundquist as its new Chief Financial Officer, Treasurer, and...
🟢 Outlook Therapeutics is trading 8.13% up today despite no direct catalyst confirmed
Outlook Therapeutics is trading 8.13% up at $0.67, supported by broader market strength despite no newly identified company-specific announcement on August 27,...
🟢 Outlook Therapeutics is trading 5.3% up in pre-market with no new company-specific announcement identified
Outlook Therapeutics is trading 5.33% up now at $0.67 in pre-market, though no new company-specific announcement was identified for August 26, 2026. - Latest...
🟢 Outlook Therapeutics is trading 10% up today amid stronger biotech sentiment
Outlook Therapeutics is trading 10.36% up now at $0.67, primarily supported by stronger biotechnology sentiment, with XBI up 2.06% during regular trading...
🟢 Outlook Therapeutics is trading 5% up today as Nasdaq rises 0.69%
Outlook Therapeutics is trading at $0.64, up 5.09%, as the Nasdaq rises 0.69%, providing a favorable backdrop for risk-sensitive biotechnology shares. - No...
🔴 Outlook Therapeutics is trading 5% down today as Nasdaq and S&P 500 decline
Outlook Therapeutics is trading 5.41% down at $0.61 now amid broader market weakness on August 24, 2026. - The Nasdaq Composite is down 0.78% and the S&P 500...
🔴 Outlook Therapeutics is trading 6.14% down today after discounted $55 million stock-and-warrant offering
Outlook Therapeutics is trading 6.14% down now at $0.64 as investors continue to absorb the impact of its discounted $55 million stock-and-warrant offering. -...
Outlook Therapeutics Got Its FDA Win — But Can a $9,000 Quarter and Massive Dilution Survive Until the U.S. Launch?
Shares of Outlook Therapeutics cratered to $0.68 — down 41% in a single week — after a one-two punch of dismal third-quarter results and a heavily dilutive...
🔴 Outlook Therapeutics is trading 10.1% down today after $9 thousand in third-quarter revenue
Outlook Therapeutics is trading at $0.68, down 10.1% now, after its August 14 earnings release showed only $9 thousand in third-quarter revenue. - The U.S....
🔴 Outlook Therapeutics is trading 5.5% down today after Q3 revenue fell to $9 thousand
Outlook Therapeutics is trading at $0.71, down -5.54%, after weak Q3 revenue and recent financing. • Q3 revenue was only $9 thousand, versus $1.505 million a...
🟢 Outlook Therapeutics is trading 6.11% up in pre-market after two sharply weaker sessions
Outlook Therapeutics is trading 6.11% up at $0.80 in pre-market, possibly reflecting a rebound after two sharply weaker sessions. - It closed at $0.76 on...
🟢 Outlook Therapeutics is trading 5.62% up today in after-hours trading after third-quarter earnings and launch updates
Outlook Therapeutics is trading at $0.80, +5.62% in after-hours trading following third-quarter results and LYTENAVA launch updates. - Reported third-quarter...
🔴 Outlook Therapeutics is trading 15.12% down today after discounted $55 million public offering
Outlook Therapeutics is trading 15.12% down at $0.75 after investors continued selling following its discounted $55 million public offering, priced at $0.99...